Caribou Biosciences, INC

Caribou Biosciences, Inc. reported the results of its annual meeting of stockholders held on June 17, 2026, including the election of directors and ratification of its accounting firm.

Caribou Biosciences announced updated clinical trial data for its vispa-cel and CB-011 CAR-T cell therapies, showing durable responses in patients with B-NHL and multiple myeloma.

Caribou Biosciences announced its allogeneic anti-BCMA CAR-T cell therapy, CB-011, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for relapsed or refractory multiple myeloma.

Caribou Biosciences reported its fourth quarter and full year 2025 financial results, highlighting strong clinical progress for its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011.

Caribou Biosciences announced positive clinical data for its CAR-T cell therapies vispa-cel and CB-011, alongside its third quarter 2025 financial results.

Caribou Biosciences announced positive preliminary financial results and compelling clinical data from its ANTLER and CaMMouflage Phase 1 trials for allogeneic CAR-T cell therapies vispa-cel and CB-011.

Caribou Biosciences reported a net loss of $27.5 million for Q3 2025, alongside positive clinical data for vispa-cel and CB-011, and strategic pipeline prioritization.

Caribou Biosciences reports increased losses and significant restructuring, discontinuing two clinical programs and reducing its workforce by 32% to focus on lead CAR-T candidates.

Caribou Biosciences reports a net loss of $39.991 million for Q1 2025 and announces strategic pipeline prioritization with workforce and cost reduction initiatives.

Caribou Biosciences' third-quarter report reveals a complex picture of financial challenges and clinical advancements in its CRISPR-based cell therapy programs.

Caribou Biosciences reported a net loss of $78.9 million for the first half of 2024, while advancing its allogeneic CAR-T cell therapy programs.

Caribou Biosciences reports a net loss of $41.2 million for the first quarter of 2024, alongside updates on its clinical programs and financial position.

Caribou Biosciences announced promising Phase 1 clinical trial results for its CAR-T cell therapies vispa-cel and CB-011, but faces significant operating losses and requires substantial additional financing for pivotal trials.

Caribou Biosciences details its 2024 financial performance and outlines key strategic advancements in its allogeneic CAR-T cell therapy programs.

Caribou Biosciences has approved bonuses, salary increases, and equity grants for key executives, including President and CEO Rachel E. Haurwitz, Chief Financial Officer Jason V. OByrne, and Chief Legal Officer Barbara G. McClung.

Caribou Biosciences' Chief Technology Officer, Timothy P. Kelly, sold 6,228 shares of common stock for $1.93 per share under a pre-arranged Rule 10b5-1 trading plan.

Caribou Biosciences CTO Timothy P. Kelly reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Caribou Biosciences' Chief Legal Officer, Barbara G. McClung, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Caribou Biosciences' Chief Business Officer, Ruhi Ahmad Khan, reported the acquisition of restricted stock units and stock options, alongside a sale of common stock to cover tax obligations.

Caribou Biosciences' Chief Medical Officer, Tina M. Albertson, received grants of restricted stock units and stock options, alongside a non-discretionary sale of shares to cover tax obligations.

Caribou Biosciences, Inc. director Ran Zheng was granted options to purchase 45,000 shares of common stock at an exercise price of $1.80 per share.

Caribou Biosciences has issued its 2026 proxy statement, outlining director elections, auditor ratification, and a proposal to amend its certificate of incorporation to provide officer exculpation.

Caribou Biosciences is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule after receiving a deficiency letter.

Caribou Biosciences has scheduled its 2025 Annual Meeting for June 12, 2025, and is seeking stockholder votes on director elections, auditor ratification, a potential reverse stock split, and meeting adjournment if necessary.

Caribou Biosciences seeks stockholder approval for a reverse stock split to maintain its Nasdaq listing and improve stock marketability.

Caribou Biosciences has scheduled its 2024 Annual Meeting for June 13, 2024, and is urging stockholders to vote on key proposals, including the election of directors and ratification of the company's accounting firm.

Caribou Biosciences will hold its 2024 annual meeting of stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Caribou Biosciences, Inc. CEO Rachel E. Haurwitz and The City Canyon Family Trust have increased their beneficial ownership in the company to 5%, reflecting a renewed significant insider stake.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.0% passive ownership stake in Caribou Biosciences, Inc. as of June 30, 2025.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.86% in Caribou Biosciences Inc., indicating a passive investment below the 5% reporting threshold.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.8% passive beneficial ownership stake in Caribou Biosciences, Inc. as of March 31, 2025.

Bank of America Corporation has filed an amended Schedule 13G, disclosing a 2.2% passive beneficial ownership stake in Caribou Biosciences, Inc. as of December 31, 2024.